The Motley Fool··Prosper Junior BakinyCRISPR Therapeutics' Gene-Editing Pipeline Targets $100B+ Cardiovascular Market
CRISPR Therapeutics advances promising pipeline candidates CTX310 and CTX320 targeting cardiovascular disease, though company remains unprofitable with minimal revenue.
CRSPgene therapyType 1 diabetes